

Resource Summary Report

Generated by [NIF](#) on Sep 2, 2026

Anti-Human CD3-170Er

RRID:AB_2811085

Type: Antibody

Proper Citation

(Standard BioTools Cat# 3170001B, RRID:AB_2811085)

Antibody Information

URL: http://antibodyregistry.org/AB_2811085

Proper Citation: (Standard BioTools Cat# 3170001B, RRID:AB_2811085)

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Mass Cytometry

Antibody Name: Anti-Human CD3-170Er

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: UCHT1

Antibody ID: AB_2811085

Vendor: Standard BioTools

Catalog Number: 3170001B

Record Creation Time: 20260218T234918+0000

Record Last Update: 20260828T175225+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Human CD3-170Er.

No alerts have been found for Anti-Human CD3-170Er.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

George AF, et al. (2025) Anatomical, subset, and HIV-dependent expression of viral sensors and restriction factors. *Cell reports*, 44(1), 115202.

Christenson ES, et al. (2025) Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(15), 3182.

Sjögren T, et al. (2024) Single cell characterization of blood and expanded regulatory T cells in autoimmune polyendocrine syndrome type 1. *iScience*, 27(4), 109610.

Raeber ME, et al. (2024) Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics. *Immunity*, 57(9), 2232.

Caulier B, et al. (2024) CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. *Cell reports. Medicine*, 5(6), 101572.

van der Sluis TC, et al. (2023) OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum. *Cell reports. Medicine*, 4(3), 100939.

Ye L, et al. (2022) A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. *Cell metabolism*, 34(4), 595.

Smole A, et al. (2022) Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. *Cancer cell*, 40(12), 1470.

Salomé B, et al. (2022) NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. *Cancer cell*, 40(9), 1027.

Sullivan KD, et al. (2021) The COVIDome Explorer researcher portal. *Cell reports*, 36(7), 109527.

Esaulova E, et al. (2021) The immune landscape in tuberculosis reveals populations linked to disease and latency. *Cell host & microbe*, 29(2), 165.

Duraiswamy J, et al. (2021) Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. *Cancer cell*, 39(12), 1623.

Xie G, et al. (2021) Characterization of HIV-induced remodeling reveals differences in infection susceptibility of memory CD4+ T cell subsets in vivo. *Cell reports*, 35(4), 109038.

Galbraith MD, et al. (2021) Seroconversion stages COVID19 into distinct pathophysiological states. eLife, 10.

Dhariwala MO, et al. (2020) Developing Human Skin Contains Lymphocytes Demonstrating a Memory Signature. Cell reports. Medicine, 1(8), 100132.

Eccles JD, et al. (2020) T-bet⁺ Memory B Cells Link to Local Cross-Reactive IgG upon Human Rhinovirus Infection. Cell reports, 30(2), 351.

Colomb F, et al. (2020) Sialyl-LewisX Glycoantigen Is Enriched on Cells with Persistent HIV Transcription during Therapy. Cell reports, 32(5), 107991.